You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

autologous stem-cell transplantation (ASCT)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    Lymphoma Trial in New York (rituximab, bendamustine, melphalan)

    Active, not recruiting
    • Lymphoma
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jan 10, 2023

    Multiple Myeloma Trial (Melphalan and Treosulfan, Melphalan)

    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    Dec 5, 2022

    ASCT Versus Chemotherapy as First-Line Consolidation Therapy

    Completed
    • T-cell Lymphoma Adults
    • consolidation with ASCT
    • (no location specified)
    Nov 25, 2023

    Autologous Stem Cell Transplantation, Conditioning Trial in Xi'an (modified BEAM, BEAM)

    Not yet recruiting
    • Autologous Stem Cell Transplantation
    • Conditioning
    • Xi'an, Shaanxi, China
      First Affiliated Hospital of Xian Jiaotong University
    Apr 14, 2023

    Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)

    Recruiting
    • Multiple Myeloma
    • Torino, TO, Italy
      Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
    May 25, 2022

    Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

    Recruiting
    • Multiple Myeloma
    • Autologous hematopoietic stem cell transplantation
    • C-CAR088
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Nov 21, 2022

    B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

    Recruiting
    • B-cell Lymphoma
    • ASCT+CAR-T Cell Infusion
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    Multiple Myeloma Trial in Philadelphia (CART-19 cells)

    Terminated
    Has Results
    • Multiple Myeloma
    • CART-19 cells
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 4, 2023

    Lymphoma, Autologous Hematopoietic Stem Cell Transplantation Trial in Xi'an (Improved BEAM regimen)

    Not yet recruiting
    • Lymphoma
    • Autologous Hematopoietic Stem Cell Transplantation
    • Improved BEAM regimen
    • Xi'an, Shaanxi, China
      First Affiliated Hospital of Xi'an Jiaotong University
    Dec 26, 2022

    Multiple Myeloma Trial in Saint Petersburg (Melphalan, Nivolumab, Autologous Stem Cell Transplantation)

    Recruiting
    • Multiple Myeloma
    • Saint Petersburg, Russian Federation
      Boris V Afanasyev, MD, Prof.
    Apr 4, 2022

    Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell Trial in Austria, Switzerland (BeEAM, BEAM)

    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • +2 more
    • Linz, Austria
    • +3 more
    Jul 29, 2021

    Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

    Recruiting
    • Multiple Myeloma
    • +2 more
    • Wuhan, Hubei, China
      Institute of Hematology, Union Hospital, Tongji Medical College,
    Nov 18, 2023

    Multiple Myeloma Trial in Berne (Melphalan, Bendamustine)

    Completed
    • Multiple Myeloma
    • Berne, Switzerland
      Department for Medical Oncology University Hospital/Inselspital
    Jul 29, 2021

    Diffuse Large B Cell Lymphoma Trial in Saint Louis (Blinatumomab, Autologous stem cell transplant, Carmustine)

    Active, not recruiting
    • Diffuse Large B Cell Lymphoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    May 4, 2022

    Hodgkin's Lymphoma Trial in Poland (drug, diagnostic test, procedure)

    Recruiting
    • Hodgkin's Lymphoma
    • Bydgoszcz, Poland
    • +12 more
    Dec 23, 2021

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

    Withdrawn
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +9 more
    • Autologous Hematopoietic Stem Cell Transplantation
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Lymphoma, Myeloma, High-dose Chemo Trial in Berne (Pedometer-based activity monitoring after ASCT)

    Recruiting
    • Lymphoma
    • +3 more
    • Pedometer-based activity monitoring after ASCT
    • Berne, Switzerland
      Departement of Medical Oncology, University Hospital Berne
    Jul 29, 2021

    Maintenance With Bortezomib Plus Daratumumab After Induction

    Recruiting
    • Multiple Myeloma
    • Non-eligible for Autologous Stem Cell Transplantation (ASCT)
    • Arganda Del Rey, Spain
    • +31 more
    Sep 15, 2022

    Diffuse, Large B-Cell, Lymphoma Trial in Italy (GA101_DHAP)

    Completed
    • Diffuse, Large B-Cell, Lymphoma
    • Vicenza, VI, Italy
    • +9 more
    Mar 3, 2022

    Multiple Myeloma Trial in Worldwide (Iberdomide)

    Recruiting
    • Multiple Myeloma
    • Nantes, France
    • +3 more
    Aug 16, 2022

    Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

    Active, not recruiting
    • Malignant Non-Hodgkin Lymphomas
    • CD34+ cell selection
    • Berne, Switzerland
      Department for Medical Oncology; University Hospital/Inselspital
    Jul 29, 2021

    Large B-cell Lymphoma Trial in Tianjin (CNCT19, Gemcitabine Injection, busulfan)

    Recruiting
    • Large B-cell Lymphoma
    • CNCT19
    • +3 more
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jan 24, 2022

    Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma Trial in Tianjin (PD-1 inhibitor)

    Recruiting
    • Hodgkin Lymphoma, Adult
    • +2 more
    • PD-1 inhibitor
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Dec 14, 2021

    Multiple Myeloma, Stem Cell Transplant Complications Trial in Boston (PARE, Waitlist Control Group)

    Not yet recruiting
    • Multiple Myeloma
    • Stem Cell Transplant Complications
    • PARE
    • Waitlist Control Group
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 30, 2023